Enfortumab-vedotin plus pembrolizumab offers survival benefits but is less cost-effective than gemcitabine and cisplatin plus nivolumab, especially in Europe. Healthcare providers face challenges ...
The implementation of an RFID solution based on web services is demonstrated. The solution has three components. Never miss a story ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results